Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| OCTO/Oxford | Other Identifier | Trial coordinating centre |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| oxBRC | UNKNOWN |
| Vodafone UK Foundation | UNKNOWN |
| Centre for Statistics in Medicine | OTHER |
| Oncology Clinical Trials Office (OCTO, Oxford) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To develop a system to manage side effects and adjust chemotherapy dose such that a patient can receive their personal maximum tolerated dose.
Patients with metastatic colorectal or breast cancer will be recruited.
All patients will be given a mobile phone onto which they will enter any side-effects experienced prior to taking capecitabine in the morning and evening. Any grade 3 or 4 symptoms will trigger an alert to a pager held by the ward-staff for immediate attention. Thus, patients' severe side-effects will be monitored in real time and the trial will allow real-time dose reductions during cycles and dose-increases at clinics. Patient experience in the trial will also be evaluated during their participation in the trial.
Patients will already be receiving the drug prior to this study and will not be administered to patients as part of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| capecitabine 2000mg/m2 (Colorectal) | capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX) | ||
| capecitabine 2500mg/m2 (Colorectal) | capecitabine 2500mg/m2 d 1-14, q 3 weekly | ||
| capecitabine 2000mg/m2 (Breast) | capecitabine 2000mg/m2d 1-14, q 3 weekly | ||
| docetaxel 75mg/m2 (Breast) | capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Toxicities (frequency at each of grades 2, 3 and 4, over all cycles) | At the end of each cycle and at occurrence |
| Measure | Description | Time Frame |
|---|---|---|
| Number of inappropriate dose adaptations and self care advice messages generated ['inappropriate' defined by nurse overriding generated advice | At occurrence | |
| Frequency of patients receiving each piece of advice from the system, including recommendations on dose and on self-treating side effects. |
Not provided
Inclusion Criteria:
For metastatic colorectal cancer:
For metastatic breast cancer:
Exclusion Criteria:
Not provided
Not provided
Not provided
Primary care clinic
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oxford Cancer Centre, Churchill Hospital | Oxford | OX3 7LJ | United Kingdom |
Not provided
| Label | URL |
|---|---|
| Oncology Clinical Trials Office (OCTO) | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D001943 | Breast Neoplasms |
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
| At occurrence |
| Obtain descriptive information on amount and duration of drug delivery (stage 2 only) Number of patients who, dose reduce stay at same dose dose increase Total dose delivery Chemotherapy duration | Twice daily |
| Obtain feedback from staff on using the system Staff recommendations for changes or improvements to the system throughout the course of the study and Semi-structured interviews | weekly for staff recommendations and one semi structured interview will take place |
| Test and refine mobile phone and server software systems Frequency of occurrence of technological faults (for example, problems caused by no phone reception) | At occurrence |
| Patient Experience EvaluationPatient experience will be evaluated as detailed in Patient Experience Evaluation | At least twice during their participation in the trial but not all patients may need to be interviewed |
| Evaluate safety outcomes Total number of grade 3/4 toxicities throughout the study period Degree of toxicity experienced Number of alerts, split by severity | End of each cycle and at occurrence |
| Dose intensity in mg/m2/week and toxicities as for stage 1 | Once at the end of the study for each patient |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |